Citalopram Administration Does Not Promote Function or Histological Recovery after Spinal Cord Injury

Int J Mol Sci. 2020 Jul 17;21(14):5062. doi: 10.3390/ijms21145062.

Abstract

Citalopram is a selective serotonin reuptake inhibitor, and although widely used as an antidepressant, this drug has also demonstrated interesting repairing properties leading to motor recovery and pathology amelioration in animal models of stroke and degeneration. Here, we tested the efficacy of both 7-day and 8-week citalopram treatment in a contusive spinal cord injury (SCI) rat model. A combination of behavioral tests, histological and serum cytokine analysis was used to assess overall recovery. Despite promoting a mild reduction of inflammatory cells as well as an early, but transient increase of specific serum cytokines, citalopram administration showed no overall beneficial effects on motor performance or lesion extension. Our results do not support citalopram treatment as a therapeutic strategy for SCI.

Keywords: 5-HT; SSRI; citalopram; motor recovery; spinal cord injury.

MeSH terms

  • Animals
  • Citalopram / administration & dosage
  • Citalopram / therapeutic use*
  • Disease Models, Animal
  • Female
  • Rats
  • Rats, Wistar
  • Recovery of Function / drug effects
  • Selective Serotonin Reuptake Inhibitors / administration & dosage
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Spinal Cord / drug effects
  • Spinal Cord / pathology
  • Spinal Cord / physiopathology
  • Spinal Cord Injuries / drug therapy*
  • Spinal Cord Injuries / pathology
  • Spinal Cord Injuries / physiopathology
  • Treatment Outcome

Substances

  • Serotonin Uptake Inhibitors
  • Citalopram